GT Biopharma (GTBP) vs Exicure (XCUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GT Biopharma is the larger company by market cap ($6.3 million vs $5.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | XCUR |
|---|---|---|
| Share price | $2.96 | $0.9001 |
| Market cap | $6.33M | $5.89M |
| 1-day change | -6.92% | -12.82% |
| YTD return | +277.07% | — |
| 1-year return | +303.27% | — |
| 5-year return | -97.77% | — |
| EPS (TTM) | $-128.61 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | $-28.35M | $-4.95M |
| 52-week high | $23.60 | $9.48 |
| 52-week low | $2.87 | $0.777 |
| Distance from 52-week high | -87.46% | -90.51% |
| Analyst consensus | none | — |
| Avg. price target upside | +2433.78% | — |
| Average volume | 78.16K | 53.56K |
| Shares outstanding | 2.14M | 6.55M |
| Employees | 1 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Exicure
XCUR stock →Exicure, Inc. does not have significant operations.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
GTBP vs XCUR FAQ
Which is bigger, GT Biopharma or Exicure?
GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $5.89M for Exicure (XCUR).
Are GT Biopharma and Exicure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.